Clinical Research in Hepatology in the COVID‐19 Pandemic and Post‐Pandemic Era: Challenges and the Need for Innovation
The severe acute respiratory syndrome coronavirus 2 pandemic has drastically altered all facets of clinical care and research. Clinical research in hepatology has had a rich tradition in several domains, including the discovery and therapeutic development for diseases such as hepatitis B and C and s...
Saved in:
Published in | Hepatology (Baltimore, Md.) Vol. 72; no. 5; pp. 1819 - 1837 |
---|---|
Main Authors | , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Wolters Kluwer Health, Inc
01.11.2020
John Wiley and Sons Inc |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The severe acute respiratory syndrome coronavirus 2 pandemic has drastically altered all facets of clinical care and research. Clinical research in hepatology has had a rich tradition in several domains, including the discovery and therapeutic development for diseases such as hepatitis B and C and studying the natural history of many forms of chronic liver disease. National Institutes of Health, foundation, and industry funding have provided important opportunities to advance the academic careers of young investigators while they strived to make contributions to the field. Instantaneously, however, all nonessential research activities were halted when the pandemic started, forcing those involved in clinical research to rethink their research strategy, including a shift to coronavirus disease 2019 research while endeavoring to maintain their preexisting agenda. Strategies to maintain the integrity of ongoing studies, including patient follow‐up, safety assessments, and continuation of investigational products, have included a shift to telemedicine, remote safety laboratory monitoring, and shipping of investigational products to study subjects. As a revamp of research is being planned, unique issues that face the research community include maintenance of infrastructure, funding, completion of studies in the predetermined time frame, and the need to reprogram career path timelines. Real‐world databases, biomarker and long‐term follow up studies, and research involving special groups (children, the homeless, and other marginalized populations) are likely to face unique challenges. The implementation of telemedicine has been dramatically accelerated and will serve as a backbone for the future of clinical research. As we move forward, innovation in clinical trial design will be essential for conducting optimized clinical research. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Potential conflict of interest: Dr. Verna received grants from Salix. Dr. Loomba consults for, advises for, and received grants from Boehringer Ingelheim, Bristol‐Myers Squibb, Cirius, Eli Lilly, Galmed, Gilead, Intercept, Janssen, Merck, NGM, Pfizer, Prometheus, and Siemens. He consults for and advises for Anylam/Regeneron, Arrowhead, AstraZeneca, Bird Rock, Celgene, CohBar, Conatus, Gemphire, Glympse, GNI, GRI, Inipharm, Ionis, Metacrine, Novartis, Novo Nordisk, Promethera, Sanofi, and Viking. He received grants from Allergan, Galectin, GE, Grail, Madrigal, NuSirt, and pH Pharma. Dr. Everson is employed by and owns stock in HepQuant. Dr. Fried consults for and owns stock in TARGET. He received grants from AbbVie and Gilead. Dr. Terrault consults for Intercept and EXIGO. She received grants from Gilead, Roche, and Genentech. Dr. Chung received grants from AbbVie, Gilead, Merck, Bristol‐Myers Squibb, Boehringer Ingelheim, Janssen, Roche, Kaleido, and Synlogic. Dr. Reddy advises for and received grants from Mallinckrodt and Gilead. He received grants from Grifols, Bristol‐Myers Squibb, Intercept, Exact Sciences, NASH‐TARGET, and HCC‐TARGET. He is on the data security monitoring board for Novartis. R.L. receives funding support from NIEHS (5P42ES010337), NCATS (5UL1TR001442), NIDDK (R01DK106419, 1R01DK121378, R01 DK124318, and P30DK120515), and DOD PRCRP (CA170674P2). G.T.E. is an equity member and CEO of HepQuant LLC. M.W.F. receives fees and is a stockholder in TARGET PharmaSolutions. N.T.: research grant support (to Institution) from Gilead and Roche/Genentech. RTC: research grant support (to Institution) from AbbVie, Gilead, Merck, BMS, Janssen, Boehringer Ingelheim, Roche, Kaleido, and Synlogic. K.R.R.: advisory board: Mallinckrodt and Gilead; research support (to Institution) from Mallinckrodt, Grifols, Gilead, Merck, BMS, Intercept, Exact Sciences, NASH‐TARGET, and HCC‐TARGET. |
ISSN: | 0270-9139 1527-3350 1527-3350 |
DOI: | 10.1002/hep.31491 |